Atossa Therapeutics (ATOS) Projected to Post Quarterly Earnings on Tuesday

Posted by Editorial Team on Mar 24th, 2025

Atossa Therapeutics (NASDAQ:ATOS – Get Free Report) will likely be posting its quarterly earnings results on Tuesday, March 25th. Analysts expect Atossa Therapeutics to post earnings of ($0.06) per share for the quarter.

Atossa Therapeutics Trading Up 5.4 %

Shares of NASDAQ:ATOS opened at $0.75 on Monday. Atossa Therapeutics has a 1 year low of $0.66 and a 1 year high of $2.31. The business has a fifty day simple moving average of $0.81 and a 200 day simple moving average of $1.12. The firm has a market cap of $94.83 million, a price-to-earnings ratio of -3.43 and a beta of 1.20.

Institutional Trading of Atossa Therapeutics

A hedge fund recently raised its stake in Atossa Therapeutics stock. Bank of America Corp DE grew its stake in Atossa Therapeutics, Inc. (NASDAQ:ATOS – Free Report) by 51.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 111,475 shares of the company’s stock after buying an additional 37,809 shares during the period. Bank of America Corp DE owned approximately 0.09% of Atossa Therapeutics worth $105,000 as of its most recent SEC filing. 12.74% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Ascendiant Capital Markets increased their price objective on Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a report on Monday, December 9th. HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of Atossa Therapeutics in a report on Wednesday, March 12th.

Read Our Latest Report on ATOS

About Atossa Therapeutics

(Get Free Report)

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.